Detailed Coverage

Onesource Specialty Pharma Q1FY27 Results Show Strong Growth

Onesource Specialty Pharma's Q1FY27 revenue reached ₹449 crore, a 37% increase year-over-year. EBITDA grew 39% to ₹123.3 crore.

Reader Takeaway: Strong revenue and EBITDA growth driven by semaglutide; capacity expansion and biologics pipeline signal future potential.

What just happened

Onesource Specialty Pharma announced its financial results for the first quarter of FY27 (Q1FY27). The company reported a revenue of ₹449 crore, marking a significant 37% rise compared to the same period last year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw robust growth, increasing by 39% year-over-year to ₹123.3 crore.

Why this matters

These results indicate strong operational execution and demand for the company's products, particularly within its semaglutide portfolio. The significant revenue and EBITDA growth, coupled with expanding margins, suggest efficient operations and effective scaling. This performance is crucial for investor confidence and signals the company's ability to capitalize on market opportunities.

The backstory

Onesource Specialty Pharma is a Contract Development and Manufacturing Organization (CDMO). The company has been focusing on expanding its capacity and strengthening its biologics business. Its semaglutide portfolio, supplying a significant portion of generic pen brands in India, has been a key revenue driver.

What changes now

The company is progressing with its expansion plans, including the commercialization of a second cartridge line in Q2 FY27. This is expected to support further volume growth. The strong performance in Q1FY27 and reaffirmed FY28 outlook of $400 million in organic revenue with a 40% steady-state EBITDA margin provide a positive outlook.

Risks to watch

While the growth trajectory is positive, investors should monitor the successful commercialization of new capacity additions and the conversion of the growing biologics Request for Proposal (RFP) funnel into secured contracts. Any delays or underperformance in these areas could impact future growth.

Peer comparison

(No specific peer data available in the filing.)

Context metrics (time-bound)

• Q1FY27 Revenue: ₹449 crore (up 37% YoY)
• Q1FY27 EBITDA: ₹123.3 crore (up 39% YoY)
• Q1FY27 EBITDA Margin: 27.5% (up 43 basis points YoY)
• Adjusted PAT: ₹63.7 crore (up 72% YoY)

What to track next

Investors will be keen to observe the performance of the new cartridge line when it becomes commercial in Q2 FY27. Additionally, tracking the progress and conversion rate of the biologics business's expanding RFP funnel will be critical indicators for future growth momentum.